Detalles de la búsqueda
1.
Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy.
Int J Mol Sci;
25(5)2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38474108
2.
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
Am J Hematol;
98(5): 730-738, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36869876
3.
Serum Procalcitonin Levels in Newly Diagnosed Hodgkin Lymphoma: Correlation with Other Inflammatory Biomarkers.
Medicina (Kaunas);
58(10)2022 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36295492
4.
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP.
Oncologist;
26(7): 597-609, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33870594
5.
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Hematol Oncol;
39(3): 336-348, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33583077
6.
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
Ann Hematol;
100(9): 2279-2292, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33523289
7.
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Am J Hematol;
95(5): 465-471, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048329
8.
Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents.
Oral Dis;
26(5): 955-966, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32011077
9.
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Br J Haematol;
184(4): 536-546, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30460684
10.
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.
Blood;
129(4): 456-459, 2017 01 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-27872060
11.
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Ann Hematol;
98(6): 1383-1392, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30877373
12.
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
Hematol Oncol;
36(1): 174-181, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28219112
13.
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol;
97(9): 1671-1682, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29756171
14.
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol;
97(9): 1747, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29943159
15.
Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation.
Eur J Haematol;
100(2): 131-139, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29105864
16.
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Am J Hematol;
98(9): E226-E229, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340832
17.
Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.
J Bone Miner Metab;
36(4): 399-409, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28660376
18.
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Lancet Oncol;
18(2): 241-250, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27956157
19.
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Eur J Haematol;
99(5): 409-414, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28675766
20.
Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
Oncologist;
21(3): 343-53, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26921291